Total Payments
$123,964
2024 Payments
$18,360
Companies
29
Transactions
150
Medicare Patients
433
Medicare Billing
$89,914
Payment Breakdown by Category
Consulting$93,959 (75.8%)
Other$19,715 (15.9%)
Travel$5,912 (4.8%)
Food & Beverage$2,922 (2.4%)
Research$1,445 (1.2%)
Education$10.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $93,959 | 80 | 75.8% |
| Honoraria | $17,420 | 7 | 14.1% |
| Travel and Lodging | $5,912 | 25 | 4.8% |
| Food and Beverage | $2,922 | 31 | 2.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,795 | 3 | 1.4% |
| Unspecified | $1,445 | 2 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $500.00 | 1 | 0.4% |
| Education | $10.85 | 1 | 0.0% |
Payments by Type
General
$122,519
148 transactions
Research
$1,445
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $32,550 | 23 | $0 (2024) |
| Merck Sharp & Dohme LLC | $23,645 | 29 | $0 (2022) |
| CSL Behring | $14,720 | 18 | $0 (2024) |
| Pharmacosmos Therapeutics Inc. | $7,600 | 3 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $7,529 | 6 | $0 (2023) |
| Incyte Corporation | $5,895 | 8 | $0 (2018) |
| Vertex Pharmaceuticals Incorporated | $5,671 | 12 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $4,870 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $3,809 | 9 | $0 (2017) |
| GlaxoSmithKline, LLC. | $2,950 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,360 | 23 | Janssen Research & Development, LLC ($9,600) |
| 2023 | $15,830 | 15 | Janssen Research & Development, LLC ($9,150) |
| 2022 | $17,285 | 13 | Janssen Research & Development, LLC ($8,400) |
| 2021 | $16,125 | 14 | Pharmacosmos Therapeutics Inc. ($7,600) |
| 2020 | $2,860 | 7 | CSL Behring ($2,125) |
| 2019 | $13,735 | 18 | Merck Sharp & Dohme Corporation ($6,664) |
| 2018 | $25,776 | 34 | CSL Behring ($6,995) |
| 2017 | $13,993 | 26 | Merck Sharp & Dohme Corporation ($6,892) |
All Payment Transactions
150 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 12/03/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $225.00 | General |
| Category: Immunology | ||||||
| 10/17/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $771.93 | General |
| 10/14/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/30/2024 | Medexus Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| 09/20/2024 | ZOLL Medical Corporation | Defibrillator (Device) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: Resuscitation | ||||||
| 08/14/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| 08/07/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 06/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 05/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 04/24/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 04/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 03/27/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/26/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 02/22/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Eurofins Viracor, LLC | — | Food and Beverage | In-kind items and services | $283.13 | General |
| 02/08/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 02/02/2024 | RECORDATI_RARE_DISEASES_INC. | — | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| 02/01/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 01/08/2024 | Halozyme Inc | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 12/25/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 12/14/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,445 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 101 | 186 | $71,080 | $14,195 |
| 2022 | 5 | 120 | 308 | $125,338 | $25,892 |
| 2021 | 3 | 93 | 255 | $86,481 | $20,340 |
| 2020 | 4 | 119 | 402 | $119,452 | $29,487 |
Total Patients
433
Total Services
1,151
Medicare Billing
$89,914
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 55 | 102 | $41,856 | $8,040 | 19.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 58 | $16,124 | $3,885 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 13 | $9,466 | $1,593 | 16.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 13 | $3,634 | $676.68 | 18.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 158 | $63,042 | $13,744 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 109 | $43,579 | $8,661 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 13 | $9,264 | $1,514 | 16.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 12 | 14 | $5,670 | $1,267 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 14 | $3,783 | $705.98 | 18.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 143 | $47,937 | $11,461 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 74 | $29,526 | $6,634 | 22.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 28 | 38 | $9,018 | $2,244 | 24.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 150 | $53,506 | $13,431 | 25.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 53 | 200 | $54,392 | $13,243 | 24.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 31 | 41 | $7,523 | $1,770 | 23.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 11 | 11 | $4,031 | $1,044 | 25.9% |
About Dr. Joseph Antin, MD
Dr. Joseph Antin, MD is a Hematology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861469249.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Antin, MD has received a total of $123,964 in payments from pharmaceutical and medical device companies, with $18,360 received in 2024. These payments were reported across 150 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($93,959).
As a Medicare-enrolled provider, Antin has provided services to 433 Medicare beneficiaries, totaling 1,151 services with total Medicare billing of $89,914. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Boston, MA
- Active Since 03/03/2006
- Last Updated 12/15/2017
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1861469249
Products in Payments
- Monoferric (Drug) $7,600
- EMPAVELI (Drug) $4,565
- PROMACTA (Drug) $3,845
- IMBRUVICA (Drug) $3,809
- Empaveli (Drug) $2,964
- NUCALA (Biological) $2,950
- PREVYMIS (Drug) $1,242
- Fabhalta (Drug) $1,025
- Defitelio (Drug) $550.00
- JAKAFI (Drug) $550.00
- Spectra Optia Apheresis System (Device) $400.00
- Defibrillator (Device) $375.00
- REZUROCK (Drug) $150.00
- Soliris (Drug) $150.00
- DIFICID (Drug) $10.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Boston
Jacalyn Rosenblatt, M.d, M.D
Hematology — Payments: $1.6M
Hematology $1.6M
Jorge Castillo, Md, MD
Hematology — Payments: $922,724
Hematology $922,724
Dr. Edward Benz, Md, MD
Hematology — Payments: $746,999
Hematology $746,999
Andrew Evens, Do, Ms, DO, MS
Hematology — Payments: $339,696
Hematology $339,696
Dr. Caron Jacobson, Md, MD
Hematology — Payments: $294,282
Hematology $294,282
Lynn Bry, Md, MD
Hematology — Payments: $285,993
Hematology $285,993